Liquidia (NASDAQ:LQDA) Insider Sells $270,611.64 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 4,134 shares of Liquidia stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $65.46, for a total value of $270,611.64. Following the completion of the transaction, the insider owned 67,132 shares of the company’s stock, valued at $4,394,460.72. This trade represents a 5.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Performance

Shares of LQDA stock opened at $71.23 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The business has a 50 day moving average of $49.85 and a two-hundred day moving average of $40.89. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $72.71. The company has a market cap of $6.33 billion, a P/E ratio of 508.82 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The firm’s revenue was up 4187.1% on a year-over-year basis. As a group, analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC raised its holdings in Liquidia by 1.1% during the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after purchasing an additional 90,400 shares in the last quarter. Vanguard Group Inc. raised its holdings in Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after purchasing an additional 52,671 shares in the last quarter. Opaleye Management Inc. raised its holdings in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares in the last quarter. Bank of America Corp DE raised its holdings in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Finally, Caprock Group LLC raised its holdings in Liquidia by 9.3% during the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after purchasing an additional 151,832 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on LQDA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday, June 5th. Raymond James Financial restated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Finally, Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).